This article was originally published in Start Up
Sequella Inc. believes that the technology to meet antibiotic-resistant mycobacterium tuberculosis already exists. The company will acquire intellectual property rights to product opportunities in TB.
You may also be interested in...
Overcoming drug resistance is a key goal of development--but will anyone fund it?
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.